GNLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Genelux Corp (GNLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has speculative buy ratings and promising analyst targets, the lack of recent positive catalysts, weak financial performance, and neutral trading sentiment make it a hold. The technical indicators also do not suggest a clear entry point.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 55.632, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting the stock is in a downward trend. Key support and resistance levels are Pivot: 2.552, R1: 2.735, S1: 2.369, R2: 2.849, S2: 2.255.
Analyst ratings remain speculative but optimistic, with price targets of $20 and $31, indicating potential long-term upside. Promising clinical data for IV Olvi-Vec in lung cancer treatment, with further updates expected in 2026.
Lack of recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, revenue remained flat YoY at 8000. Net income dropped to 0, down 100% YoY. EPS improved to -0.86, up 230.77% YoY, but gross margin dropped to 0, indicating poor profitability.
Benchmark lowered the price target to $20 from $23 with a speculative buy rating. H.C. Wainwright maintains a buy rating with a $31 price target, citing promising clinical data and potential for overcoming platinum resistance in cancer treatment.
